Citation

Tse E, Chan TSY, Koh LP, Chng WJ, Kim WS, Tang T, Lim ST, Lie AKW, Kwong YL. Bone Marrow Transplant. 2014; 49(7): 902-906.

Copyright

(Copyright © 2014, Nature Publishing Group)

DOI

10.1038/bmt.2014.65

PMID

unavailable

Abstract

Eighteen patients (men=14; women=4) with natural killer (NK)/T-cell lymphomas (CR1, N=9; CR2, N=7; PR, N=1; progressive disease, N=1) undergoing allogeneic haematopoietic SCT (HSCT) (myeloablative, N=14; reduced intensity, N=4) were analyzed. With a median follow-up of 20.5 months, the 5-year OS was 57% and 5-year EFS was 51%. The use of the SMILE regimen pre-HSCT was the most important positive prognostic indicator, resulting in significantly superior OS and EFS (P<0.01). Acute GVHD had a significant negative impact on OS (P=0.03). CR1 and CR2 patients had similar survivals, but all patients who were not transplanted in remission died. Chronic GVHD, International Prognostic Index, disease stage, primary sites of involvement, conditioning regimen and source of HSC did not affect survival. Although allogeneic HSCT leads to reasonable survival for NK/T-cell lymphoma patients, results need to be compared with those in patients receiving L-asparaginase-containing regimens. Novel prognostic models incorporating biomarkers, such as circulating EBV DNA, are needed to identify high-risk patients who may benefit from allogeneic HSCT. © 2014 Macmillan Publishers Limited.

Language: en

Keywords

Humans; adolescent; Adult; Female; Male; Middle Aged; adult; human; Adolescent; suicide; female; male; Young Adult; survival rate; clinical trial; survival time; article; controlled study; clinical article; cancer combination chemotherapy; priority journal; vincristine; middle aged; pathology; multicenter study; dexamethasone; pneumonia; cancer survival; immunosuppressive treatment; cancer staging; immunosuppressive agent; methotrexate; outcome assessment; cyclophosphamide; clinical effectiveness; prednisolone; overall survival; doxorubicin; procedures; natural killer cell; etoposide; young adult; chronic graft versus host disease; hematopoietic stem cell transplantation; Hematopoietic Stem Cell Transplantation; Transplantation, Homologous; allogeneic hematopoietic stem cell transplantation; ifosfamide; multicenter study (topic); Killer Cells, Natural; Transplantation Conditioning; cancer prognosis; acute graft versus host disease; allotransplantation; event free survival; graft infection; International Prognostic Index; Lymphoma, T-Cell; myeloablative conditioning; NK T cell lymphoma; recombinant asparaginase